{"analyses":[{"ciLowerLimit":"81.5","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"88.8","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","paramType":"Percentage of participants with response","paramValue":"85.4","statisticalMethod":"Two - sided binomial test","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"334"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"391"}],"units":"Participants"}],"description":"CR and PR are defined by the local investigator according to the current European Group for Blood and Marrow Transplantation (EBMT) criteria. According to EBMT criteria, CR is defined as the absence of serum and urine monoclonal paraprotein + no increase in size or number of lytic bone lesions; and PR is defined as not all CR criteria + 50 percentage or more reduction in serum monoclonal paraprotein.","groups":[{"description":"Cyclophosphamide + Bortezomib + Dexamethasone for three 21-day cycles","id":"OG000","title":"Cyclophosphamide + Bortezomib + Dexamethasone"}],"paramType":"NUMBER","populationDescription":"Efficacy analysis set: Participants of the safety analysis set (who received bortezomib at least once independently of accordance to the protocol) who had an evaluable investigator based assessment of success of therapy at the end of study visit (ie, assessment by local investigator as CR, PR, minimal response, stable disease, progressive disease).","reportingStatus":"POSTED","timeFrame":"Up to Day 63","title":"Participants With Complete Response (CR) + Partial Response (PR) (Efficacy Set)","type":"PRIMARY","unitOfMeasure":"Participants"}